InBody Co.Ltd
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was foun… Read more
InBody Co.Ltd (041830) - Net Assets
Latest net assets as of September 2025: ₩282.02 Billion KRW
Based on the latest financial reports, InBody Co.Ltd (041830) has net assets worth ₩282.02 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩318.34 Billion) and total liabilities (₩36.31 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩282.02 Billion |
| % of Total Assets | 88.59% |
| Annual Growth Rate | 15.48% |
| 5-Year Change | 82.52% |
| 10-Year Change | 258.9% |
| Growth Volatility | 5.54 |
InBody Co.Ltd - Net Assets Trend (2011–2024)
This chart illustrates how InBody Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for InBody Co.Ltd (2011–2024)
The table below shows the annual net assets of InBody Co.Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩273.90 Billion | +9.63% |
| 2023-12-31 | ₩249.83 Billion | +16.06% |
| 2022-12-31 | ₩215.26 Billion | +17.16% |
| 2021-12-31 | ₩183.73 Billion | +22.44% |
| 2020-12-31 | ₩150.06 Billion | +7.43% |
| 2019-12-31 | ₩139.69 Billion | +12.31% |
| 2018-12-31 | ₩124.39 Billion | +16.82% |
| 2017-12-31 | ₩106.48 Billion | +15.36% |
| 2016-12-31 | ₩92.30 Billion | +20.94% |
| 2015-12-31 | ₩76.32 Billion | +28.03% |
| 2014-12-31 | ₩59.61 Billion | +15.62% |
| 2013-12-31 | ₩51.56 Billion | +11.76% |
| 2012-12-31 | ₩46.13 Billion | +9.47% |
| 2011-12-31 | ₩42.14 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to InBody Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 28044380747000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩280.44 Billion | 102.74% |
| Common Stock | ₩6.84 Billion | 2.51% |
| Total Equity | ₩272.97 Billion | 100.00% |
InBody Co.Ltd Competitors by Market Cap
The table below lists competitors of InBody Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Bashi Media Co Ltd
SHG:600386
|
$208.22 Million |
|
Ganzhou Yihao New Materials Co. Ltd. A
SHE:301176
|
$208.22 Million |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
$208.23 Million |
|
S.Biomedics Co. Ltd.
KQ:304360
|
$208.32 Million |
|
Chongqing QinAn M&E PLC
SHG:603758
|
$208.14 Million |
|
Strata Critical Medical, Inc.
NASDAQ:SRTA
|
$208.13 Million |
|
Suzhou Cheersson Precision Metal Fo
SHE:002976
|
$208.10 Million |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
$208.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InBody Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 248,765,778,270 to 272,966,153,430, a change of 24,200,375,160 (9.7%).
- Net income of 33,142,757,260 contributed positively to equity growth.
- Dividend payments of 4,559,396,450 reduced retained earnings.
- Share repurchases of 7,163,089,300 reduced equity.
- Other factors increased equity by 2,780,103,650.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩33.14 Billion | +12.14% |
| Dividends Paid | ₩4.56 Billion | -1.67% |
| Share Repurchases | ₩7.16 Billion | -2.62% |
| Other Changes | ₩2.78 Billion | +1.02% |
| Total Change | ₩- | 9.73% |
Book Value vs Market Value Analysis
This analysis compares InBody Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.31x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩6780.37 | ₩29250.00 | x |
| 2017-12-31 | ₩7897.32 | ₩29250.00 | x |
| 2018-12-31 | ₩9225.66 | ₩29250.00 | x |
| 2019-12-31 | ₩10501.73 | ₩29250.00 | x |
| 2020-12-31 | ₩11519.66 | ₩29250.00 | x |
| 2021-12-31 | ₩14104.32 | ₩29250.00 | x |
| 2022-12-31 | ₩16524.35 | ₩29250.00 | x |
| 2023-12-31 | ₩19096.39 | ₩29250.00 | x |
| 2024-12-31 | ₩20954.12 | ₩29250.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InBody Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.14%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.21%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.12x
- Recent ROE (12.14%) is below the historical average (15.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 13.23% | 17.54% | 0.72x | 1.05x | ₩1.35 Billion |
| 2012 | 12.23% | 16.98% | 0.69x | 1.04x | ₩1.03 Billion |
| 2013 | 12.01% | 16.84% | 0.69x | 1.04x | ₩1.04 Billion |
| 2014 | 14.90% | 18.14% | 0.77x | 1.06x | ₩2.92 Billion |
| 2015 | 22.68% | 25.11% | 0.84x | 1.08x | ₩9.68 Billion |
| 2016 | 18.40% | 21.27% | 0.82x | 1.05x | ₩7.76 Billion |
| 2017 | 18.15% | 20.72% | 0.83x | 1.05x | ₩8.67 Billion |
| 2018 | 15.81% | 19.74% | 0.76x | 1.06x | ₩7.23 Billion |
| 2019 | 14.62% | 17.45% | 0.76x | 1.11x | ₩6.46 Billion |
| 2020 | 11.67% | 16.35% | 0.64x | 1.11x | ₩2.51 Billion |
| 2021 | 18.52% | 24.69% | 0.68x | 1.11x | ₩15.66 Billion |
| 2022 | 15.71% | 21.13% | 0.66x | 1.13x | ₩12.29 Billion |
| 2023 | 14.76% | 21.56% | 0.62x | 1.10x | ₩11.85 Billion |
| 2024 | 12.14% | 16.21% | 0.67x | 1.12x | ₩5.85 Billion |
Industry Comparison
This section compares InBody Co.Ltd's net assets metrics with peer companies in the Healthcare Equipment & Supplies industry.
Industry Context
- Industry: Healthcare Equipment & Supplies
- Average net assets among peers: $81,663,683,380
- Average return on equity (ROE) among peers: -9.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InBody Co.Ltd (041830) | ₩282.02 Billion | 13.23% | 0.13x | $208.16 Million |
| MEDIANA Co.Ltd (041920) | $34.91 Billion | 20.29% | 0.27x | $70.69 Million |
| Value Added Technology Co. Ltd (043150) | $349.29 Billion | 22.01% | 0.46x | $109.99 Million |
| MEKICS Co Ltd (058110) | $7.87 Billion | -24.74% | 1.89x | $14.44 Million |
| Meta Biomed Co. Ltd (059210) | $39.05 Billion | 3.02% | 0.38x | $50.83 Million |
| INFINITT Healthcare Co. Ltd (071200) | $77.28 Billion | 6.38% | 0.20x | $53.10 Million |
| i-SENS Inc (099190) | $118.81 Billion | 12.18% | 0.38x | $127.37 Million |
| Sewoon Medical Co. Ltd (100700) | $46.71 Billion | 7.88% | 0.18x | $34.07 Million |
| CU Medical Systems Inc (115480) | $58.36 Billion | 16.15% | 0.51x | $14.81 Million |
| PeopleBio Inc (304840) | $2.70 Billion | -148.07% | 0.61x | $5.72 Million |